Piramal Pharma Limited (PPLPHARMA) - Net Assets
Based on the latest financial reports, Piramal Pharma Limited (PPLPHARMA) has net assets worth Rs80.74 Billion INR (≈ $873.15 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs161.89 Billion ≈ $1.75 Billion USD) and total liabilities (Rs81.16 Billion ≈ $877.68 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Piramal Pharma Limited to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs80.74 Billion |
| % of Total Assets | 49.87% |
| Annual Growth Rate | 18.65% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 25.18 |
Piramal Pharma Limited - Net Assets Trend (2021–2025)
This chart illustrates how Piramal Pharma Limited's net assets have evolved over time, based on quarterly financial data. Also explore PPLPHARMA total assets for the complete picture of this company's asset base.
Annual Net Assets for Piramal Pharma Limited (2021–2025)
The table below shows the annual net assets of Piramal Pharma Limited from 2021 to 2025. For live valuation and market cap data, see PPLPHARMA company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs81.25 Billion ≈ $878.74 Million |
+2.71% |
| 2024-03-31 | Rs79.11 Billion ≈ $855.58 Million |
+16.80% |
| 2023-03-31 | Rs67.73 Billion ≈ $732.53 Million |
+1.15% |
| 2022-03-31 | Rs66.97 Billion ≈ $724.21 Million |
+63.31% |
| 2021-03-31 | Rs41.01 Billion ≈ $443.47 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Piramal Pharma Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 84.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs10.49 Billion | 12.91% |
| Common Stock | Rs13.24 Billion | 16.30% |
| Other Comprehensive Income | Rs10.15 Billion | 12.49% |
| Other Components | Rs47.37 Billion | 58.30% |
| Total Equity | Rs81.25 Billion | 100.00% |
Piramal Pharma Limited Competitors by Market Cap
The table below lists competitors of Piramal Pharma Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Foot Locker Inc
NYSE:FL
|
$2.29 Billion |
|
ARIS MNG.CORP.
F:ZP1
|
$2.30 Billion |
|
Mister Car Wash, Inc. Common Stock
NASDAQ:MCW
|
$2.30 Billion |
|
Krungthai Card Public Company Limited
BK:KTC-R
|
$2.30 Billion |
|
Epoxy Base Electronic Material Corp Ltd
SHG:603002
|
$2.29 Billion |
|
Suzhou Gold Mantis Construction Decoration Co Ltd
SHE:002081
|
$2.29 Billion |
|
Inv La Constru
SN:ILC
|
$2.29 Billion |
|
Braze Inc
NASDAQ:BRZE
|
$2.29 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Piramal Pharma Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 79,113,700,000 to 81,254,700,000, a change of 2,141,000,000 (2.7%).
- Net income of 911,300,000 contributed positively to equity growth.
- Dividend payments of 144,700,000 reduced retained earnings.
- Other comprehensive income increased equity by 1,218,200,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs911.30 Million | +1.12% |
| Dividends Paid | Rs144.70 Million | -0.18% |
| Other Comprehensive Income | Rs1.22 Billion | +1.5% |
| Other Changes | Rs156.20 Million | +0.19% |
| Total Change | Rs- | 2.71% |
Book Value vs Market Value Analysis
This analysis compares Piramal Pharma Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.64x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 4.78x to 2.64x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-03-31 | Rs33.56 | Rs160.30 | x |
| 2022-03-31 | Rs55.03 | Rs160.30 | x |
| 2023-03-31 | Rs55.86 | Rs160.30 | x |
| 2024-03-31 | Rs61.64 | Rs160.30 | x |
| 2025-03-31 | Rs60.63 | Rs160.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Piramal Pharma Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.12%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.00%
- • Asset Turnover: 0.58x
- • Equity Multiplier: 1.93x
- Recent ROE (1.12%) is below the historical average (3.63%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 13.94% | 9.71% | 1.02x | 1.40x | Rs1.61 Billion |
| 2022 | 5.61% | 5.73% | 0.51x | 1.91x | Rs-2.94 Billion |
| 2023 | -2.75% | -2.63% | 0.49x | 2.14x | Rs-8.64 Billion |
| 2024 | 0.23% | 0.22% | 0.53x | 1.94x | Rs-7.73 Billion |
| 2025 | 1.12% | 1.00% | 0.58x | 1.93x | Rs-7.21 Billion |
Industry Comparison
This section compares Piramal Pharma Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $35,979,469,852
- Average return on equity (ROE) among peers: 17.85%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Piramal Pharma Limited (PPLPHARMA) | Rs80.74 Billion | 13.94% | 1.01x | $2.29 Billion |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $1.14 Billion | 5.77% | 1.16x | $27.95 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.01 Billion | 13.28% | 2.64x | $390.72 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $13.86 Billion | -0.01% | 0.47x | $790.23 Million |
| Abbott India Limited (ABBOTINDIA) | $1.88 Billion | 54.31% | 0.66x | $5.84 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $5.93 Billion | 39.42% | 0.60x | $3.92 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $925.81 Million |
| Alkem Laboratories Limited (ALKEM) | $49.85 Billion | 12.66% | 0.54x | $6.93 Billion |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $1.26 Billion | 16.93% | 0.29x | $179.06 Million |
| Alembic Pharmaceuticals Limited (APLLTD) | $31.90 Billion | 25.98% | 0.88x | $1.63 Billion |
| Aurobindo Pharma Limited (AUROPHARMA) | $245.74 Billion | 10.78% | 0.38x | $8.64 Billion |
About Piramal Pharma Limited
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, i… Read more